title: Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond.
abstract: Many current chemotherapies function by damaging genomic DNA in rapidly dividing cells ultimately leading to cell death. This therapeutic approach differentially targets cancer cells that generally display rapid cell division compared to normal tissue cells. However, although these treatments are initially effective in arresting tumor growth and reducing tumor burden, resistance and disease progression eventually occur. A major mechanism underlying this resistance is increased levels of cellular DNA repair. Most cells have complex mechanisms in place to repair DNA damage that occurs due to environmental exposures or normal metabolic processes. These systems, initially overwhelmed when faced with chemotherapy induced DNA damage, become more efficient under constant selective pressure and as a result chemotherapies become less effective. Thus, inhibiting DNA repair pathways using target specific small molecule inhibitors may overcome cellular resistance to DNA damaging chemotherapies. Non-homologous end joining a major mechanism for the repair of double-strand breaks (DSB) in DNA is regulated in part by the serine/threonine kinase, DNA dependent protein kinase (DNA-PK). The DNA-PK holoenzyme acts as a scaffold protein tethering broken DNA ends and recruiting other repair molecules. It also has enzymatic activity that may be involved in DNA damage signaling. Because of its' central role in repair of DSBs, DNA-PK has been the focus of a number of small molecule studies. In these studies specific DNA-PK inhibitors have shown efficacy in synergizing chemotherapies in vitro. However, compounds currently known to specifically inhibit DNA-PK are limited by poor pharmacokinetics: these compounds have poor solubility and have high metabolic lability in vivo leading to short serum half-lives. Future improvement in DNA-PK inhibition will likely be achieved by designing new molecules based on the recently reported crystallographic structure of DNA-PK. Computer based drug design will not only assist in identifying novel functional moieties to replace the metabolically labile morpholino group but will also facilitate the design of molecules to target the DNA-PKcs/Ku80 interface or one of the autophosphorylation sites.
authors: Department of Oncology, Segal Cancer Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University Montreal, QC, Canada.
authors: David
authors: D
authors: Davidson
authors: Lilian
authors: L
authors: Amrein
authors: Lawrence
authors: L
authors: Panasci
authors: Raquel
authors: R
authors: Aloyz
keywords: DNA damage; DNA repair; DNA-PK; DNA-PK inhibitors; DNA-PKcs
references: Nat Rev Mol Cell Biol. 2006 Oct;7(10):739-50
references: 16926856
references: DNA Repair (Amst). 2006 Sep 8;5(9-10):1042-8
references: 16822724
references: Biochem Soc Trans. 2001 May;29(Pt 2):196-201
references: 11356153
references: Curr Opin Cell Biol. 2001 Apr;13(2):225-31
references: 11248557
references: Nucleic Acids Res. 2011 Jul;39(13):5757-67
references: 21450809
references: N Engl J Med. 2009 Feb 5;360(6):563-72
references: 19196673
references: Oncogene. 2005 Feb 3;24(6):949-61
references: 15592499
references: DNA Repair (Amst). 2006 May 10;5(5):575-90
references: 16567133
references: PLoS Genet. 2008 Jun 27;4(6):e1000110
references: 18584027
references: Carcinogenesis. 2012 Mar;33(3):538-47
references: 22226916
references: DNA Repair (Amst). 2005 Sep 28;4(10):1172-81
references: 16046194
references: Lancet. 2007 Jul 14;370(9582):143-152
references: 17630037
references: J Cell Biol. 2007 Apr 23;177(2):219-29
references: 17438073
references: Leuk Res. 2011 Aug;35(8):1080-6
references: 21281966
references: Cancer J. 2010 May-Jun;16(3):214-9
references: 20526099
references: Br J Cancer. 2005 Oct 31;93(9):1011-8
references: 16249792
references: Eur J Med Chem. 2012 Nov;57:85-101
references: 23059543
references: J Biol Chem. 2008 Jan 4;283(1):1-5
references: 17999957
references: Bioorg Med Chem. 2011 Jul 1;19(13):3983-94
references: 21664823
references: Biochem Biophys Res Commun. 1996 Apr 16;221(2):207-12
references: 8619835
references: J Biol Chem. 1994 Feb 18;269(7):5241-8
references: 8106507
references: Cell Signal. 2011 Aug;23(8):1273-80
references: 21514376
references: Cancer Res. 2005 Jun 15;65(12):4987-92
references: 15958537
references: Biochem Soc Trans. 2009 Feb;37(Pt 1):265-72
references: 19143644
references: Ann N Y Acad Sci. 2005 Dec;1066:243-58
references: 16533929
references: Cancer Res. 2003 Mar 15;63(6):1198-201
references: 12649176
references: DNA Repair (Amst). 2006 Sep 8;5(9-10):1234-45
references: 16793349
references: Nucleic Acids Res. 2003 Oct 1;31(19):5501-12
references: 14500812
references: Blood. 2011 Mar 31;117(13):3575-84
references: 21245486
references: Cell Cycle. 2010 Jul 1;9(13):2529-36
references: 20543558
references: Apoptosis. 2011 Nov;16(11):1165-76
references: 21809047
references: Invest New Drugs. 2012 Jun;30(3):1248-56
references: 21221710
references: J Pharmacol Exp Ther. 2006 Feb;316(2):946-54
references: 16258022
references: Mol Cell Biol. 2011 Apr;31(8):1719-33
references: 21300785
references: J Natl Cancer Inst. 2009 Sep 2;101(17):1174-81
references: 19657108
references: Free Radic Biol Med. 2010 May 15;48(10):1435-43
references: 20193758
references: Blood. 2004 Jun 15;103(12):4659-65
references: 15010369
references: Nucleic Acids Res. 2008 Jul;36(12):4088-98
references: 18539610
references: BMC Mol Biol. 2010 Mar 06;11:18
references: 20205745
references: Cell. 2002 Mar 22;108(6):781-94
references: 11955432
references: Bioorg Med Chem Lett. 2003 Sep 15;13(18):3083-6
references: 12941339
references: Cancer Res. 2006 May 15;66(10):5354-62
references: 16707462
references: Mol Cancer Ther. 2003 Dec;2(12):1257-64
references: 14707266
references: Mutat Res. 2009 Jan 15;660(1-2):66-73
references: 19028508
references: Cancer Res. 2004 Apr 1;64(7):2390-6
references: 15059890
references: Bioorg Med Chem Lett. 2011 Feb 1;21(3):966-70
references: 21216595
references: Carcinogenesis. 2003 Oct;24(10):1571-80
references: 12919958
references: Trends Mol Med. 2008 Sep;14(9):373-80
references: 18693139
references: DNA Repair (Amst). 2010 Dec 10;9(12):1307-14
references: 21030321
references: Mutat Res. 2011 Jun 3;711(1-2):73-86
references: 21376743
references: Mol Cancer Res. 2011 Dec;9(12):1696-707
references: 22009179
references: Cancer Chemother Pharmacol. 2012 Jan;69(1):155-64
references: 21630086
references: Mol Cell. 2009 May 15;34(3):285-97
references: 19450527
references: Nat Rev Cancer. 2012 Mar 22;12(4):278-87
references: 22437872
references: Mol Cancer Res. 2003 Oct;1(12):913-20
references: 14573792
references: Mutat Res. 2012 Oct-Dec;751(2):158-246
references: 22743550
references: Gynecol Oncol. 2008 Jul;110(1):93-8
references: 18589211
references: Nature. 2010 Jan 7;463(7277):118-21
references: 20023628
references: J Biol Chem. 2005 Apr 15;280(15):14709-15
references: 15677476
references: Neoplasia. 2011 Nov;13(11):1069-80
references: 22131882
references: Invest New Drugs. 2012 Aug;30(4):1736-42
references: 21567185
references: Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):1023-30
references: 22138455
references: Biochem Biophys Res Commun. 2008 Nov 7;376(1):52-5
references: 18755145
references: J Cell Physiol. 2005 Feb;202(2):492-502
references: 15389585